• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Black men less likely to receive follow-up for elevated prostate cancer marker, PSA

bys25qthea
April 7, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Black men under 65 are less likely to receive recommended diagnostic follow-up testing after an elevated prostate specific antigen (PSA) result than white men of the same age. 

2. Poor diagnostic follow-up may help explain higher rates of prostate cancer mortality among black men. 

Study Rundown: This study found that black men under 65 were significantly less likely to receive appropriate follow-up testing after an elevated PSA screening test compared to white men of the same age. This is concerning because black men are at higher risk for developing prostate cancer and experience higher rates of prostate cancer mortality. These findings generate questions regarding whether racial differences in follow-up to the racial disparity in mortality due to treatment delay and whether racial differences in access to care is responsible since this racial disparity in follow-up was significant only in men >65, ineligible for Medicare.

A key limitation of this study is that the reason for lack of follow-up was not assessed, whether it was due to patient non-compliance, lack of provider recommendation, or lack of access. Without clear characterization of the barriers to follow-up, interventions cannot be developed. Moreover, PSA screening is a limited test and only represents one step of many in the diagnosis and treatment of prostate cancer. Further studies are needed to definitively link lower rates of follow-up testing to differences in mortality.

Click to read the study in Cancer 

Click to read an accompanying editorial in Cancer 

RELATED REPORTS

Variation in prostate cancer screening rates associated with subsequent metastatic prostate cancer incidence

#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

#VisualAbstract: Prostate-Specific Membrane Antigen Positron Emission Tomography can be used to detect pelvic lymph nodes in prostate cancer

In Depth [secondary analysis of a prospective, randomized trial]: The study used data from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to evaluate the relationship between race and diagnostic follow-up care after an elevated PSA (prostate-specific antigen) level. Men who had a PSA level >4 ng/mL at any time during the study were included and follow-up was a composite variable defined as repeat PSA, a prostate biopsy or both within 9 months. Self-identified racial group and multiple secondary variables were included in a mixed-effect multivariable model. Results were stratified by age, (<65 or >=65) to account for Medicare eligibility.

Of the 6924 eligible men with an elevated PSA, 4,413 (70%) underwent follow-up within 9 months. Black men <65 years were 45% less likely to undergo follow-up than white men of the same age (OR=0.55, 95% CI, 0.37-0.82, p=.003). There was no racial difference seen in men 65 and older. 

By Maren Shapiro and Leah Hawkins

More from this author: More U.S. women using emergency contraception pill, No cost contraception reduces unintended pregnancies, Active-Duty U.S. servicewomen have higher rates of unintended pregnancy

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: PLCOprostate specific antigenPSA
Previous Post

Group incentives promote employee weight loss

Next Post

The RE-LY trial: Dabigatran non-inferior to warfarin in preventing strokes in patients with atrial fibrillation [Classics Series]

RelatedReports

Patient Basics: Prostate-Specific Antigen Blood Test (PSA Test)
Oncology

Variation in prostate cancer screening rates associated with subsequent metastatic prostate cancer incidence

October 30, 2022
#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival
StudyGraphics

#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

October 26, 2022
#VisualAbstract: Prostate-Specific Membrane Antigen Positron Emission Tomography can be used to detect pelvic lymph nodes in prostate cancer
StudyGraphics

#VisualAbstract: Prostate-Specific Membrane Antigen Positron Emission Tomography can be used to detect pelvic lymph nodes in prostate cancer

October 7, 2021
#VisualAbstract: Prevalence of toxigenic and non-toxigenic asymptomatic Clostridioides difficile colonization in pediatric populations
StudyGraphics

#VisualAbstract: Magnetic resonance imaging-targeted biopsy noninferior to standard biopsy for prostate cancer screening

August 12, 2021
Next Post
Classics Series, Landmark Trials in Medicine

The RE-LY trial: Dabigatran non-inferior to warfarin in preventing strokes in patients with atrial fibrillation [Classics Series]

Classics Series, Landmark Trials in Medicine

The AFFIRM trial: Rate-control vs. rhythm-control in atrial fibrillation [Classics Series]

New clinical prediction model helps emergency physicians identify high-priority febrile children

New clinical prediction model helps emergency physicians identify high-priority febrile children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options